Champions Oncology, Inc.
CSBR · NASDAQ
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Revenue | $15,035 | $13,995 | $12,355 | $17,039 |
| % Growth | 7.4% | 13.3% | -27.5% | – |
| Cost of Goods Sold | $7,619 | $8,353 | $7,665 | $7,015 |
| Gross Profit | $7,416 | $5,642 | $4,690 | $10,024 |
| % Margin | 49.3% | 40.3% | 38% | 58.8% |
| R&D Expenses | $2,616 | $2,082 | $1,963 | $1,719 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4,615 | $4,067 | $4,441 | $3,806 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,231 | $6,149 | $6,404 | $5,525 |
| Operating Income | $185 | -$507 | -$1,714 | $4,499 |
| % Margin | 1.2% | -3.6% | -13.9% | 26.4% |
| Other Income/Exp. Net | $70 | $55 | -$250 | $19 |
| Pre-Tax Income | $255 | -$452 | -$1,964 | $4,518 |
| Tax Expense | $18 | $14 | -$129 | $23 |
| Net Income | $299 | -$436 | -$1,834 | $4,495 |
| % Margin | 2% | -3.1% | -14.8% | 26.4% |
| EPS | 0.019 | -0.032 | -0.13 | 0.33 |
| % Growth | 161.4% | 75.7% | -139.4% | – |
| EPS Diluted | 0.019 | -0.032 | -0.13 | 0.31 |
| Weighted Avg Shares Out | 13,792 | 13,788 | 13,754 | 13,701 |
| Weighted Avg Shares Out Dil | 14,458 | 13,788 | 13,754 | 14,365 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $357 | $358 | $394 | $398 |
| EBITDA | $612 | -$94 | -$1,570 | $4,916 |
| % Margin | 4.1% | -0.7% | -12.7% | 28.9% |